

EUROGIN 2017 - Amsterdam - October 8-11, 2017

HPV Induced Cancers - Exploring Knowledge, Priorities and Visions

		Auditorium (1000 - level 0)	G 102 (160 /level 1)	G 104 (110 /level 1)	G 105 (110 /level 1)	G 106-107 (270 lev 1)	
Sunday - Oct 8	8.30	10.00	MTC1 - Global focus on HPV infection to diseases: the rising knowledge by sites and gender	W2 - Workshop on HPV Immunization	W1 - Advanced Colposcopy Course (access with Full Congress Pass only or separate registration)	HN01 - Natural history of HNSCC	
	Coffee Break					Coffee Break	
	10.30	12.00	MTC2 Cervical cancer control in high income countries - current standards and challenges	W2 - Workshop on HPV Immunization		HN02 - Epidemiology of HPV driven HNSCC	Regional WS Netherlands / Flanders - in Dutch/Flemish language
	12.15	13.30		Satellite symposium INCELL		HN03 - submitted papers	Lunchbreak 12.10 - 13.10
	13.45	15.30	MTC3 Cervical cancer control in low and middle resource countries	W3 - TC for CC Screening Coordinators and Evaluators	W4 - Vulvar Diseases Course I	HN04 - Evidence and controversies on impact of HPV on OPC	Regional WS / Netherlands / Flanders Coffee break 15.10 - 15.40
	Coffee Break						
	16.00	17.30	MTC4 New Horizons in translational research	W3 - TC for CC Screening Coordinators and Evaluators	W4 - Vulvar Diseases Course II (Vulvodynia)	HN05 - Management of HPV driven OPC	Regional WS Netherlands / Flanders
	17.30	19.00	FC (Free Communications) 01 Screening methods 1	FC02 Low Resource Settings	FC03 - Genital Neoplasia	HN06 - submitted papers	FC04 - HPV negative cancers
	19.15		Opening Ceremony				

		Auditorium (1000 - level 0)	G 102-103 (300 /level 1)	G 104 (120 /level 1)	G 105 (110 /level 1)	G 106-107 (270 /level 1)	
Monday - Oct 9	8.00	09:30	MSS1 Gender-neutral HPV vaccination, challenging elimination of HPV and HPV-associated cancers	SS01 HPV assays: from available HPV tests to the next generation of testing	FC05 - HPV testing 1	HN07 - Update on immunotherapy trials in HNSCC	CS01 Primary HPV vs co-testing - debate session
	09:30	11.00	MSS2 Long term protection of screening and vaccination programs	SS02 HPV communication challenges	FC06 - Epidemiology 1	HN08 - Early antigen HPV serology in head & neck cancer	CS02 Cervical cancer screening guidelines
	Coffee Break						
	11.30	12.45	Satellite symposium MSD				
	13.00	14.15	Satellite Symposium Qiagen				
	14.15	15.45	MSS3 Triage of HPV-positive women	SS03 HPV related cancers in immunocompromised recipients	W5 - Workshop francophone (in French)	HN09 - Screening and prevention in HPV-driven OPC	FC07 - Vaccines 1
	Coffee Break						
	16.15	17.45	MSS4 Consequences of implementation of HPV screening for cervical cancer	SS04 Therapeutics against HPV and related diseases	W5 - Workshop francophone (in French)	HN10 - Recurrent respiratory papillomatosis	FC08 - Self-sampling
17.45	19.15	Satellite symposium HOLOGIC	SS05 - HPV in non-genital, non-oral cancers				

			Auditorium (1000 - level 0)	G 102-103 (300 /level 1)	G 104-105 (270 /level 1)	G 106 (110 /level 1)	G 107 (110 /level 1)		
Tuesday - Oct 10	8.00	9.30	MSS5 Targeting high risk populations for HPV associated cancers (cervix, anus, OP)	FC09 - Vaccines 2	CS03 Building consensus for the adoption of self-sampling in cervical cancer screening	FC10 - HPV testing 2	FC12 - Methylation (ends 9.45)		
	9.30	11.00	MSS6 Discovery of new biomarkers, the clinical value of the predictors as a signature of pre-cancers	SS06 - 20 years of HPV research - long term follow-up	CS04 Reproductive morbidity after treatment for CIN	FC11 - Screening 1	FC13 - Modelling (starts 9.45)		
	Coffee Break								
	11.30	12.45	Satellite symposium BD						
	13.00	14.15	Satellite symposium ROCHE						
	14.15	15.45	MSS7 Impact of national HPV vaccine programs, a decade on	SS07 Renewed population screening for cervical cancer in The Netherlands / followed by lab excursion	CS 05 Risk of HPV transmission among males and females	SS09 - Vaginal microbiome in women	FC14 - WACC / Health Education		
	Coffee Break								
	16.15	16.45	SS11 - Vaccine surveillance: monitoring adverse events and safety program evaluation	SS08 Screening regimens in vaccinated women (previous and new generation of vaccines)	CS06 Colposcopy	SS10 - HPV-induced anal cancer	FC15 - WACC / Health Education		
		17.45							
	17.45	19.15	SS12 What have we learnt from population-wide HPV vaccination programs	FC17 - Screening 2	FC18 - Diagnostic procedures	FC19 - Epidemiology 2	FC16 - Molecular and biological markers 1		
Wednesday - Oct 11				G 102-103 (300 /level 1)	G 104 (110 /level 1)	G 105 (110 /level 1)	G 106 (110 /level 1)	G 107 (110 /level 1)	
	8.00	9.30	SS13 Vaccines, beyond the scope: targeting populations at risk	SS16 - CISNET	CS07 Post treatment follow-up	FC20- Self, urine and plasma sampling	W6 - Workshop in Spanish language (8.00 - 10.30)		
	9.30	11.00	SS14 CoheaHr	SS17 Epidemiology - natural history	CS08 Anal HPV infection and diseases in women	FC21 - Screening methods 2			
	11.00	12.30	SS15 HPV Faster	SS18 Immunology and serology	FC23 - Males and anus	FC22 - Molecular and biological markers 2	W7 - Workshop in Portuguese language (10.30 - 13.30)		
	12.30	13.30							

MTC	MTC: Main Training Course
MSS	MSS: Main Scientific Session
SS	SS: Scientific Session
CS	CS: Clinical Session
FC	FC: Free Communications
HN	HN: Head & Neck sessions
LW	Regional Workshop (Netherlands)
W 2-7	W: specialized workshops and training courses / workshops in other languages
W 1	Advanced Colposcopy Course (special registration required)